Drugs / Nabiximols
Nabiximols
also known as
Sativex · GW-1000-02 · Cannabis Based Medicine Extract · Cannabis sativa L., folium cum flore · GW 1000 · Nabidiolex · SAB378 · Tetranabinex
Trials 49 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 110 trials | ||||||
| Phase 1 | NCT05503147 | Mar 2022 → Aug 2023 | eating disorder, impaired renal function disease, nutritional deficiency disease | Ove Andersen | Unknown | No outcome recorded |
| Phase 1 | NCT02325024 | Jan → Oct 2016 | impaired renal function disease | GW Pharmaceuticals Ltd | Withdrawn | No outcome recorded |
| Phase 1 | NCT02432612 | Oct 2015 → Oct 2016 | cancer of unknown primary site | GW Pharmaceuticals Ltd | Withdrawn | No outcome recorded |
| Phase 1 | NCT02325011 | Nov 2014 → Feb 2015 | — | Jazz Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01975688 | Feb 2014 → Mar 2015 | head and neck squamous cell carcinoma | GW Pharmaceuticals Ltd | Terminated | No outcome recorded |
| Phase 1 | NCT01887301 | Jul 2013 → May 2014 | — | Jazz Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01323465 | Feb → Mar 2008 | — | Jazz Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01323569 | Feb → Jun 2008 | — | Jazz Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01322464 | Jan → Feb 2008 | — | Jazz Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01037608 | May 2007 → Aug 2011 | cannabis dependence, substance abuse | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01812616 | Sep 2014 → Jun 2016 | cancer | Jazz Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/2 | NCT01812603 | Sep 2013 → Jan 2015 | cancer | Jazz Pharmaceuticals | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT05974293 | Dec 2026 → Apr 2027 | neuromyelitis optica | Michael, Levy M.D.,Ph.D. | Withdrawn | No outcome recorded |
| Phase 2 | NCT05629702 | Feb 2023 → Sep 2026 expected | brain neoplasm, glioblastoma | University of Birmingham | Recruiting | No outcome recorded |
| Phase 2 | NCT01747850 | Mar 2013 → Nov 2015 | cannabis dependence | Centre for Addiction and Mental Health | Completed | No outcome recorded |
| Phase 2 | NCT00723918 | Apr 2009 → Jan 2010 | polyneuropathy | Washington University School of Medicine | Withdrawn | No outcome recorded |
| Phase 2 | NCT00530764 | Nov 2007 → Jan 2010 | cancer | GW Pharmaceuticals Ltd | Completed | No outcome recorded |
| Phase 2 | NCT00202423 | Jul 2005 → ? | multiple sclerosis | S. Andrea Hospital | Unknown | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT04592159 | Feb 2021 → Mar 2023 | post-traumatic stress disorder | Jazz Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT01776970 | Jan 2013 → Dec 2015 | amyotrophic lateral sclerosis | Ospedale San Raffaele | Completed | No outcome recorded |
| Phase 327 trials | ||||||
| Phase 3 | NCT04984278 | Aug 2021 → Nov 2022 | multiple sclerosis | Jazz Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT04657666 | Dec 2020 → May 2022 | — | Jazz Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT04203498 | Oct 2020 → Feb 2023 | multiple sclerosis | Jazz Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT03087201 | Apr 2018 → Nov 2020 | Tourette syndrome | Hannover Medical School | Completed | No outcome recorded |
| Phase 3 | NCT01424566 | Jun 2012 → Jul 2015 | — | Jazz Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01538225 | Apr 2012 → Nov 2013 | multiple sclerosis | Almirall, S.A. | Completed | No outcome recorded |
| Phase 3 | NCT01361607 | May 2011 → Nov 2014 | — | Jazz Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01337089 | Jan 2011 → Jan 2016 | — | Jazz Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01262651 | Nov 2010 → Jul 2015 | — | GW Pharmaceuticals Ltd | Completed | No outcome recorded |
| Phase 3 | NCT00681538 | Jan 2008 → Jan 2009 | multiple sclerosis | Jazz Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00702468 | Nov 2007 → Jan 2009 | multiple sclerosis | Jazz Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00713817 | Mar → Jul 2007 | peripheral neuropathy | Jazz Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00391079 | Sep 2006 → Apr 2008 | multiple sclerosis | GW Pharmaceuticals Ltd | Completed | No outcome recorded |
| Phase 3 | NCT00710554 | Aug 2005 → Oct 2006 | peripheral neuropathy | Jazz Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00710424 | Jul 2005 → Jun 2006 | diabetic neuropathy | Jazz Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01599234 | Mar → Dec 2005 | multiple sclerosis | Jazz Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00678795 | Aug 2002 → Oct 2005 | multiple sclerosis, urinary bladder disorder | Jazz Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01606202 | Jul 2002 → Jan 2005 | — | Jazz Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00711646 | Jun 2002 → Mar 2004 | multiple sclerosis | Jazz Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00711880 | May 2002 → Mar 2004 | peripheral neuropathy | Jazz Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00675948 | Apr 2002 → Sep 2006 | cancer | Jazz Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01606176 | Mar → Aug 2002 | multiple sclerosis | Jazz Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01604265 | Mar → Aug 2002 | multiple sclerosis, neuropathy, painful | Jazz Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00674609 | Feb 2002 → Feb 2004 | cancer | Jazz Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01606189 | Dec 2001 → Sep 2002 | — | Jazz Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01610700 | May 2001 → Jul 2002 | multiple sclerosis | Jazz Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01868048 | ? → Jun 2017 | multiple sclerosis | GW Research Ltd | Withdrawn | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT03186664 | Dec 2016 → Dec 2017 | — | IRCCS Centro Neurolesi Bonino Pulejo | Completed | No outcome recorded |
| — | NCT01748799 | Feb 2013 → Sep 2014 | cannabis dependence | Centre for Addiction and Mental Health | Completed | No outcome recorded |
Also used as a comparator or background therapy in 6 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03201835 Comparator | Sep → Dec 2015 | — | PhytoTech Therapeutics, Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01322139 Comparator | Dec 2007 → Jun 2008 | — | Jazz Pharmaceuticals | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT01898520 Comparator | Dec 2013 → Sep 2016 | cerebral palsy | Jazz Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00872144 Comparator | Jun 2010 → Dec 2012 | neuropathy, painful | Mary Lynch | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01964547 Comparator | Jan 2012 → May 2013 | multiple sclerosis | Jazz Pharmaceuticals | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04820361 Comparator | Jul 2022 → Dec 2023 | neuropathy, painful | Albina Nowak, MD | Unknown | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 64 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | nabiximols | “Nabiximols (Nabiximols is the U.S. Adopted Name [USAN] for Sativex [GW Pharma Ltd, Wiltshire, U.K.], which does not yet have an INN), a novel cannabinoid formulation, is...” PMID 22483680 ↗ Apr 201220“Nabiximols (trade name Sativex®) is an oromucosal spray formulation containing 1:1 fixed ratio of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) derived from cloned...” NCT03186664 ↗ “nabiximols (Sativex, GW Pharma Ltd. Salisbury, UK), an oromucosal spray primarily containing delta‐9‐tetrahydrocannabinol (THC) and cannabidiol (CBD).” PMID 21671456 ↗ Apr 2011 “a standardised oromucosal spray (nabiximols) containing a defined combination of delta-9-tetrahydrocannabinol and cannabidiol” PMID 30554828 ↗ Dec 2018 “with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols).” PMID 21878454 ↗ Aug 2011 “Sativex(®) (nabiximols) as an add-on therapy in alleviating bladder symptoms in patients with MS.” PMID 20829244 ↗ Sep 2010 “Δ9-tetrahydrocannabinol (THC)/cannabidiol (CBD) oromucosal spray (Sativex (®), nabiximols)” PMID 23750331 ↗ May 2013 “(USAN name, nabiximols; Sativex, GW Pharmaceuticals, Salisbury, Wiltshire, UK)” PMID 23180178 ↗ Nov 2012 “study of nabiximols* (Sativex(®) ), as add-on therapy” PMID 21362108 ↗ Mar 2011 “(U.S. Adopted Name, nabiximols; Sativex(®))” PMID 23141881 ↗ Nov 2012 |
| Known as | Cannabis Based Medicine Extract | “This is a 10-week, randomised, double blind, placebo-controlled, crossover trial to investigate the effect of Cannabis Based Medicine Extract (Sativex) on patterns of brain...” NCT00202423 ↗ |
| Known as | Cannabis sativa L., folium cum flore | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04820361 ↗ |
| Known as | GW 1000 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3833333 ↗ |
| Known as | GW-1000-02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01610700 ↗ |
| Known as | Nabidiolex | ChEMBL registry synonym — accepted as the source's own label CHEMBL3833333 ↗ |
| Known as | SAB378 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00723918 ↗ |
| Known as | Sativex | “nabiximols (Sativex, GW Pharma Ltd. Salisbury, UK), an oromucosal spray primarily containing delta‐9‐tetrahydrocannabinol (THC) and cannabidiol (CBD).” PMID 21671456 ↗ Apr 2011 |
| Known as | Tetranabinex | ChEMBL registry synonym — accepted as the source's own label CHEMBL3833333 ↗ |
| Modality | Other / unclassified | “THC/CBD oromucosal spray, a novel cannabinoid formulation” PMID 24420962 ↗ Jan 2014 |
| Route | Other | “THC/CBD oromucosal spray” PMID 23180178 ↗ Nov 2012 |